ATEC

Company Overview — What Does Alphatec Holdings, Inc. Do?

Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; Sigma transforaminal lumbar interbody fusion pedicle-based access system that provides direct visualization of anatomical landmarks; Sigma PTP Access and Patient Positioning System; squadron lateral retractor designed to maximize patient outcomes; Invictus Spinal Fixation System, a thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep System that provides minimally invasive pedicle screw placement. It also provides Invictus Modular Fixation Systems designed to increase adaptability with the power of screw modularity; OsseoScrew system to restore the integrity of the spinal column; Arsenal spinal fixation system, a comprehensive thoracolumbar fixation platform to fix a range of degenerative to deformity pathologies and surgical procedures; Aspida Anterior Lumbar Plating System, a fixation system for anterior lumbar interbody fusion; AMP Anti-Migration Plate; OCT Spinal Fixation System; trestle luxe anterior cervical plate system; and Insignia Anterior Cervical Plate System. In addition, the company offers IdentiTi Porous Ti, Transcend Lateral, and Battalion Posterior Interbody Implants; and biologics consisting of Cervical Structural Allograft Spacers, 3D ProFuse Demineralized Bone Scaffold, Neocore Osteoconductive Matrix, Alphagraft Demineralized and Cellular Bone Matrix, and Amnioshield Amniotic Tissue Barrier, as well as EOS imaging products. It sells its products through a network of independent distributors and direct sales representatives in the United States. The company was founded in 1990 and is headquartered in Carlsbad, California. Alphatec Holdings, Inc. (ATEC) is classified as a small-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Patrick S. Miles and employs approximately 700 people. With a market capitalization of $1.7B, ATEC is one of the notable companies in the Healthcare sector.

Alphatec Holdings, Inc. (ATEC) Stock Rating — Reduce (April 2026)

As of April 2026, Alphatec Holdings, Inc. receives a Reduce rating with a composite score of 36.8/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.ATEC ranks #3,181 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Alphatec Holdings, Inc. ranks #478 of 838 stocks, placing it in the lower half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).

ATEC Stock Price and 52-Week Range

Alphatec Holdings, Inc. (ATEC) currently trades at $11.11. The stock gained $0.04 (0.4%) in the most recent trading session. The 52-week high for ATEC is $23.29, which means the stock is currently trading -52.3% from its annual peak. The 52-week low is $8.81, putting the stock 26.1% above its annual trough. Recent trading volume was 1.6M shares, reflecting moderate market activity.

Is ATEC Overvalued or Undervalued? — Valuation Analysis

Alphatec Holdings, Inc. (ATEC) carries a value factor score of 35/100 in the Blank Capital model, signaling premium valuation that prices in significant future growth. The price-to-book ratio stands at 145.10x, versus the sector average of 2.75x. The price-to-sales ratio is 2.38x, compared to 1.66x for the average Healthcare stock.

At current multiples, Alphatec Holdings, Inc. trades at a premium to most Healthcare peers. This elevated valuation may be justified if the company can sustain above-average growth rates and profitability, but it also creates downside risk if earnings disappoint expectations.

Alphatec Holdings, Inc. Profitability — ROE, Margins, and Quality Score

Alphatec Holdings, Inc. (ATEC) earns a quality factor score of 26/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is -1401.4%, compared to the Healthcare sector average of -43.5%, which is below typical expectations for high-quality companies. Return on assets (ROA) comes in at -20.5% versus the sector average of -33.1%.

On a margin basis, Alphatec Holdings, Inc. reports gross margins of 69.0%, compared to 71.5% for the sector. The operating margin is -15.9% (sector: -66.1%). Net profit margin stands at -23.4%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 35.0% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.

ATEC Debt, Balance Sheet, and Financial Health

Alphatec Holdings, Inc. has a debt-to-equity ratio of 4864.0%, compared to the Healthcare sector average of 32.0%. This elevated leverage warrants close monitoring, as it increases the company's sensitivity to rising interest rates and economic downturns. The current ratio is 1.99x, suggesting adequate working capital coverage. Total debt on the balance sheet is $560M. Cash and equivalents stand at $156M.

ATEC has a beta of 0.71, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Alphatec Holdings, Inc. is 52/100, reflecting average volatility within the normal range for its sector.

Alphatec Holdings, Inc. Revenue and Earnings History — Quarterly Trend

In TTM 2026, Alphatec Holdings, Inc. reported revenue of $702M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-161M. Gross margin was 69.0%. Operating income came in at $-107M.

In Q3 2025, Alphatec Holdings, Inc. reported revenue of $197M and earnings per share (EPS) of $-0.19. Net income for the quarter was $-29M. Gross margin was 69.9%. Revenue grew 30.4% year-over-year compared to Q3 2024. Operating income came in at $-16M.

In Q2 2025, Alphatec Holdings, Inc. reported revenue of $186M and earnings per share (EPS) of $-0.27. Net income for the quarter was $-41M. Gross margin was 69.6%. Revenue grew 27.5% year-over-year compared to Q2 2024. Operating income came in at $-13M.

In Q1 2025, Alphatec Holdings, Inc. reported revenue of $169M and earnings per share (EPS) of $-0.35. Net income for the quarter was $-52M. Gross margin was 68.6%. Revenue grew 22.2% year-over-year compared to Q1 2024. Operating income came in at $-44M.

Over the past 8 quarters, Alphatec Holdings, Inc. has demonstrated a growth trajectory, with revenue expanding from $138M to $702M. Investors analyzing ATEC stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.

ATEC Dividend Yield and Income Analysis

Alphatec Holdings, Inc. (ATEC) does not currently pay a dividend. This is common among smaller companies in the Medical Equipment industry that prefer to reinvest cash flows into business expansion rather than returning capital to shareholders. Income-focused investors looking for Healthcare dividend stocks may want to explore other Healthcare stocks or use the stock screener to filter by dividend yield.

ATEC Momentum and Technical Analysis Profile

Alphatec Holdings, Inc. (ATEC) has a momentum factor score of 40/100, reflecting neutral trend characteristics. The stock is neither significantly outperforming nor underperforming the broader market on a momentum basis. The investment factor score is 24/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 65/100 reflects moderate short selling activity.

ATEC vs Competitors — Healthcare Sector Ranking and Peer Comparison

Within the Healthcare sector, Alphatec Holdings, Inc. (ATEC) ranks #478 out of 838 stocks based on the Blank Capital composite score. This places ATEC in the lower half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.

Comparing ATEC against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full ATEC vs S&P 500 (SPY) comparison to assess how Alphatec Holdings, Inc. stacks up against the broader market across all factor dimensions.

ATEC Next Earnings Date

No upcoming earnings date has been announced for Alphatec Holdings, Inc. (ATEC) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.

Should You Buy ATEC? — Investment Thesis Summary

The quantitative profile for Alphatec Holdings, Inc. suggests caution. The quality score of 26/100 flags below-average profitability. The value score of 35/100 indicates premium valuation.

In summary, Alphatec Holdings, Inc. (ATEC) earns a Reduce rating with a composite score of 36.8/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on ATEC stock.

Related Resources for ATEC Investors

Explore more research and tools: ATEC vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare ATEC head-to-head with peers: ATEC vs AZN, ATEC vs SLGL, ATEC vs VMD.